YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

Daré Bioscience, Inc. ( NASDAQ: DARE) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...

Daré will host a conference call and live webcast today, November 14, 2024, at 4:30 p.m. Eastern Time to review financial ...

Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call ...

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate - pivotal Phase 3 contra ...

Brian Kemp Dolliver; Analyst; Brookline Capital Markets Douglas Tsao; Analyst; H.C. Wainwright & Co LLC ...

Good morning and welcome to Digihost Technology Inc. Third Quarter 2024 financial results conference call. My name is Robin and I will be your operator for today’s call. Joining for us today’s ...